[en] In this review, early career and senior members of Assembly 5 (Airway Diseases, Asthma, COPD and Chronic Cough) present key recent findings pertinent to airway diseases that were presented during the European Respiratory Society International Congress 2023 in Milan, Italy, with a particular focus on asthma, COPD, chronic cough and bronchiectasis. During the congress, an increased number of symposia, workshops and abstract presentations were organised. In total, 739 abstracts were submitted for Assembly 5 and the majority of these were presented by early career members. These data highlight the increased interest in this group of respiratory diseases.
Disciplines :
General & internal medicine
Author, co-author :
Bergantini, Laura; Respiratory Disease Unit, Department of Medical Sciences, Surgery, and Neurosciences, University of Siena, Siena, Italy
Baker, James ; Division of Immunology, Immunity to Infection and Respiratory Medicine, School of Biological Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, The University of Manchester, Manchester, UK
Bossios, Apostolos ; Karolinska Severe Asthma Center, Department of Respiratory Medicine and Allergy, Karolinska University Hospital Huddinge, Stockholm, Sweden ; Division of Lung and Airway Research, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden
Braunstahl, Gert-Jan ; Franciscus Gasthuis and Vlietland Hospital, Rotterdam, The Netherlands ; Erasmus Medical Center Rotterdam, Rotterdam, The Netherlands
Conemans, Lennart H; Maastricht Universitair Medisch Centrum+, Maastricht, The Netherlands
Mathioudakis, Alexander G ; Division of Immunology, Immunity to Infection and Respiratory Medicine, School of Biological Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, The University of Manchester, Manchester, UK ; North West Lung Centre, Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK
Pobeha, Pavol; Faculty of Medicine, Pavol Jozef Safarik University, Kosice, Slovakia
Ricciardolo, Fabio Luigi Massimo ; Department of Clinical and Biological Sciences, University of Turin, Turin, Italy ; Institute of Translational Pharmacology, National Research Council (IFT-CNR), Palermo, Italy
Schleich, Florence ; Université de Liège - ULiège > Département des Sciences de l'activité physique et de la réadaptation
Snelgrove, Robert J; National Heart and Lung Institute, Imperial College London, London, UK
Trinkmann, Frederik ; Department of Pneumology and Critical Care Medicine, Thoraxklinik at Heidelberg University Hospital, Translational Lung Research Center Heidelberg, German Center for Lung Research (DZL), Heidelberg, Germany ; Department of Biomedical Informatics, Center for Preventive Medicine and Digital Health, University Medical Center Mannheim, Heidelberg University, Mannheim, Germany
Uller, Lena; Department of Experimental Medical Science, Unit of Respiratory Immunopharmacology, Lund University, Lund, Sweden
Beech, Augusta ; Division of Immunology, Immunity to Infection and Respiratory Medicine, School of Biological Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, The University of Manchester, Manchester, UK ; Medicines Evaluation Unit, Manchester University NHS Foundation Trust, Manchester, UK
Support statement: J. Baker, A.G. Mathioudakis and A. Beech were supported by the National Institute for Health and Care Research (NIHR) Manchester Biomedical Research Centre (NIHR203308). A.G. Mathioudakis was supported by an NIHR Clinical Lectureship in Respiratory Medicine. The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care. R.J. Snelgrove is a Wellcome Trust Senior Research Fellow in Basic Biomedical Sciences (209458/Z/17/Z). A. Bossios is supported by the Swedish Heart\u2013Lung Foundation (20220478 and 20210434).J. Baker, A.G. Mathioudakis and A. Beech were supported by the National Institute for Health and Care Research (NIHR) Manchester Biomedical Research Centre (NIHR203308). A.G. Mathioudakis was supported by an NIHR Clinical Lectureship in Respiratory Medicine. The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care. R.J. Snelgrove is a Wellcome Trust Senior Research Fellow in Basic Biomedical Sciences (209458/Z/17/Z). A. Bossios is supported by the Swedish Heart\u2013Lung Foundation (20220478 and 20210434).
Schleich F, Bikov A, Mathioudakis AG, et al. Research highlights from the 2018 European Respiratory Society International Congress: airway disease. ERJ Open Res 2019; 5: 00225-2018.
Lahousse L, Bahmer T, Cuevas-Ocaña S, et al. ERS International Congress, Madrid, 2019: highlights from the Airway Diseases, Asthma and COPD Assembly. ERJ Open Res 2020; 6: 00341-2019.
Beech A, Portacci A, Herrero-Cortina B, et al. ERS International Congress 2022: highlights from the Airway Diseases Assembly. ERJ Open Res 2023; 9: 00034-2023.
Stolz D, Mkorombindo T, Schumann DM, et al. Towards the elimination of chronic obstructive pulmonary disease: a Lancet Commission. Lancet 2022; 400: 921–972.
Trinkmann F, Watz H, Herth FJF. Why do we still cling to spirometry for assessing small airway function? Eur Respir J 2020; 56: 2001071.
Çolak Y, Lange P, Vestbo J, et al. Pre-COPD in young adults and COPD later in life: a population-based cross-cohort comparison study. Eur Respir J 2023; 62: Suppl. 67, PA1013.
Rapsomaniki E, Hughes R, Make B, et al. Long-term outcomes in patients with pre-COPD or PRISm in NOVELTY. Eur Respir J 2023; 62: Suppl. 67, OA4936.
Ercan S, Alpaydin AO, Canturk A, et al. The comparison of quantitative CT features of COPD and pre-COPD: results from a real-life study. Eur Respir J 2023; 62: Suppl. 67, PA2282.
Virdee S, Hogg J, Boudreau J, et al. Quantitative computed tomography assessment of pulmonary structure in cannabis smokers. Eur Respir J 2023; 62: Suppl. 67, PA2285.
Kostorz-Nosal S, Jastrzębski D, Błach A, et al. Window of opportunity for respiratory oscillometry: a review of recent research. Respir Physiol Neurobiol 2023; 316: 104135.
Valach C, Veneroni C, Wouters E, et al. Oscillometry in the assessment of early smoking-induced airway changes. Eur Respir J 2023; 62: Suppl. 67, OA4236.
Franzen KF, Buchwald I, Hauck A, et al. Impact of heated tobacco products, e-cigarettes, and combustible cigarettes on small airways and arterial stiffness. Eur Respir J 2023; 62: Suppl. 67, PA5316.
Meldrum OW, Donaldson GC, Narayana JK, et al. Mucus, microbiomes, and lung function decline in COPD. Eur Respir J 2023; 62: Suppl. 67, PA2193.
Fang H, Liu Y, Yang Q, et al. Prognostic biomarkers based on proteomic technology in COPD: a recent review. COPD 2023; 18: 1353–1365.
Haldar K, Choy DF, Yosuf A, et al. Heterogeneity of the lung microbiome influences response to astegolimab, an anti ST2, in COPD. Eur Respir J 2023; 62: Suppl. 67, PA1291.
Ferguson GT, Rabe KF, Martinez FJ, et al. Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial. Lancet Respir Med 2018; 6: 747–758.
Rothnie KJ, Müllerová H, Smeeth L, et al. Natural history of chronic obstructive pulmonary disease exacerbations in a general practice-based population with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2018; 198: 464–471.
Anzueto A. Impact of exacerbations on COPD. Eur Respir Rev 2010; 19: 113–118.
Carter V, Skinner D, Chan JSK, et al. COPD exacerbations during and beyond the COVID-19 pandemic in the UK. Eur Respir J 2023; 62: Suppl. 67, PA1014.
Lipson DA, Barnhart F, Brealey N, et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med 2018; 378: 1671–1680.
Rabe KF, Martinez FJ, Ferguson GT, et al. Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD. N Engl J Med 2020; 383: 35–48.
Venkatesan P. GOLD COPD report: 2023 update. Lancet Respir Med 2023; 11: 18.
Singh D, Bafadhel M, Bowen K, et al. Step up to ICS/LAMA/LABA versus switch to LAMA/LABA in patients with COPD on ICS/LABA: post hoc analysis of KRONOS. Eur Respir J 2023; 62: Suppl. 67, PA4687.
Stolz D, Papakonstantinou E, Pascarella M, et al. Airway smooth muscle area to predict steroid responsiveness in COPD patients receiving triple therapy (HISTORIC): a randomised, placebo-controlled, double-blind, investigator-initiated trial. Eur Respir J 2023; 62: 2300218.
Cardoso J, Ferreira AJ, Guimarães M, et al. Treatable traits in COPD – a proposed approach. Int J Chron Obstruct Pulmon Dis 2021; 16: 3167–3182.
Vogelmeier C, Simons S, Garbe E, et al. Increased risk of severe cardiovascular events following exacerbations of COPD: a multi-database cohort study. Eur Respir J 2023; 62: Suppl. 67, PA3013.
Wade R, Martinez FJ, Criner GJ, et al. ECG-derived risk factors for adverse cardiopulmonary outcomes in COPD patients: IMPACT post hoc analysis. Eur Respir J 2023; 62: Suppl. 67, OA4929.
Bhatt SP, Rabe KF, Hanania NA, et al. Dupilumab for COPD with type 2 inflammation indicated by eosinophil counts. N Engl J Med 2023; 389: 205–214.
Anzueto A, Barjaktarevic IZ, Siler TM, et al. Ensifentrine, a novel phosphodiesterase 3 and 4 inhibitor for the treatment of chronic obstructive pulmonary disease: randomized, double-blind, placebo-controlled, multicenter phase III trials (the ENHANCE trials). Am J Respir Crit Care Med 2023; 208: 406–416.
Watz H, Rheault T, Bengtsson T, et al. Inhaled ensifentrine, decreased healthcare research utilization and reduced moderate exacerbation rate and risk in COPD over 24 weeks. Eur Respir J 2023; 62: Suppl. 67, OA2602.
Rabe KF, Celli BR, Wechsler ME, et al. Safety and efficacy of itepekimab in patients with moderate-to-severe COPD: a genetic association study and randomised, double-blind, phase 2a trial. Lancet Respir Med 2021; 9: 1288–1298.
Kim RY, Oliver BG, Wark PAB, et al. COPD exacerbations: targeting IL-33 as a new therapy. Lancet Respir Med 2021; 9: 1213–1214.
Booth S, Cunoosamy D, Vestbo J, et al. Relationship between IL-33 expression and epithelial remodelling in COPD small airways. Eur Respir J 2023; 62: Suppl. 67, OA4298.
Brock J, Herth F, Darwiche K, et al. Bronchial rheoplasty for chronic bronchitis: 6-month results from the European Registry Study. Eur Respir J 2023; 62: Suppl. 67, OA2594.
Kang J, Jung JY, Ji HW, et al. Lifestyle interventions to reduce particulate matter exposure in patients with COPD. Eur Respir J 2023; 62: Suppl. 67, OA2606.
Bernasconi S, Angelucci A, Rossi A, et al. A wearable system for personal air pollution exposure: a walk-about in Milan. Eur Respir J 2023; 62: Suppl. 67, PA2908.
Rony F, Klein J, Valent A, et al. Preserving treatment for asthma and COPD patients while minimizing carbon footprint: relative lung bioavailability and total systemic exposure of a medium dose formulation of BDP/FF/ GB MDI with novel propellant. Eur Respir J 2023; 62: Suppl. 67, PA2388.
Frias DP, Vieira GL, Smelan J, et al. Anthracosis particulate matter causes changes in macrophages inflammatory response and in expression of genes related to xenobiotics metabolism in co-culture of macrophages with BEAS-2B airway cells. Eur Respir J 2023; 62: Suppl. 67, PA4047.
Baker J, Booth B, Dungwa J, et al. Alveolar macrophage carbon is associated with COPD severity. Eur Respir J 2023; 62: Suppl. 67, PA4065.
Lee K-Y, Chen K-Y, Wu S-M, et al. The clinical and pathogenetic roles of ITIH4 in particulate matter-related emphysema. Eur Respir J 2023; 62: Suppl. 67, PA1264.
Cortesi EE, Antoranz A, Geudens V, et al. Single-cell spatial proteomics depicts novel dynamics involving senescent progenitors in fibrotic lesions in COPD and IPF. Eur Respir J 2023; 62: Suppl. 67, OA1772.
Lahmar MZ, Ahmed E, Vachier I, et al. Early COPD and Hedgehog interacting protein (HHIP) polymorphisms. Eur Respir J 2023; 62: Suppl. 67, PA5206.
Ntenti C, Goulas A, Papakonstantinou E, et al. FKBP5 rs4713916: a potential genetic predictor of differential response to triple therapy among COPD patients. Eur Respir J 2023; 62: Suppl. 67, PA5200.
Baker J, McCrae C, Higham A, et al. Neutrophilic inflammation associates with dysregulated iron metabolism in COPD. Eur Respir J 2023; 62: Suppl. 67, PA3051.
Ntenti C, Goulas A, Grize L, et al. Genetic variants in the iron responsive element binding protein 2 (IREB2) are associated with spirometry parameters and cough prevalence. Eur Respir J 2023; 62: Suppl. 67, PA5198.
Park JW, Son ES, Jeong SH. MicroRNA-149-3p regulates cigarette smoke extract-induced autophagy and cellular senescence in human small airway epithelial cells (NHBE) cultured under the air–liquid interface (ALI). Eur Respir J 2023; 62: Suppl. 67, PA5199.
Baker J, Kimura G, Nishimoto Y, et al. The senolytic effect of dasatinib and quercetin on cellular senescence in COPD in vitro and in vivo models. Eur Respir J 2023; 62: Suppl. 67, PA4046.
Foisset F, Lehalle C, Nasri A, et al. Development of a bronchial epithelium with a sensory innervation both derived from induced pluripotent stem cells. Eur Respir J 2023; 62: Suppl. 67, OA892.
Nadaud M, Bourdais C, Fort-Petit A, et al. Benefits of bronchial epithelial repair by iPSC in COPD. Eur Respir J 2023; 62: Suppl. 67, PA5240.
Wang Y, Meng Z, Ming L, et al., Autologous transplantation of P63+ lung progenitor cells for chronic obstructive pulmonary disease therapy. Eur Respir J 2023; 62: Suppl. 67, OA4297.
Calzetta L, Aiello M, Frizzelli A, et al. Stem cell-based regenerative therapy and derived products in COPD: a systematic review and meta-analysis. Cells 2022; 11: 1797.
Guarnier LP, Moro LG, Lívero FAR, et al. Regenerative and translational medicine in COPD: hype and hope. Eur Respir Rev 2023; 32: 220223.
Gomez N, James V, Onion D, et al. Extracellular vesicles and chronic obstructive pulmonary disease (COPD): a systematic review. Respir Res 2022; 23: 82.
Deng M, Hou G. Small extracellular vesicles mediated pathological communications between dysfunctional airway epithelium cells and skeletal muscle cells as a novel mechanism induced skeletal muscle dysfunction in COPD. Eur Respir J 2023; 62: Suppl. 67, PA4040.
Fujimoto S, Fujita Y, Watanabe N, et al. Lipofibroblast derived-extracellular vesicles attenuate cigarette smoke-induced lung injury. Eur Respir J 2023; 62: Suppl. 67, PA5238.
Rappaport SM. Biomarkers intersect with the exposome. Biomarkers 2012; 17: 483–489.
Wild CP. Complementing the genome with an “exposome”: the outstanding challenge of environmental exposure measurement in molecular epidemiology. Cancer Epidemiol Biomarkers Prev 2005; 14: 1847–1850.
Wild CP. The exposome: from concept to utility. Int J Epidemiol 2012; 41: 24–32.
Vrijheid M. The exposome: a new paradigm to study the impact of environment on health. Thorax 2014; 69: 876–878.
Woodruff PG, Agusti A, Roche N, et al. Current concepts in targeting chronic obstructive pulmonary disease pharmacotherapy: making progress towards personalised management. Lancet 2015; 385: 1789–1798.
Agustí A, Melén E, DeMeo DL, et al. Pathogenesis of chronic obstructive pulmonary disease: understanding the contributions of gene–environment interactions across the lifespan. Lancet Respir Med 2022; 10: 512–524.
Kuks P, Karp T, Hartman J, et al. Cluster analysis to identify distinct clinical asthma phenotypes within ATLANTIS. Eur Respir J 2023; 62: Suppl. 67, OA1525.
Clemeno FA, Bell A, Richardson M, et al. Associations of imaging biomarkers with physiological markers of small airways dysfunction in asthma in the ATLANTIS study. Eur Respir J 2023; 62: Suppl. 67, OA1529.
Dierick B, Achterbosch M, Eikholt A, et al. Electronic monitoring with a digital smart spacer to support personalized inhaler use education in patients with asthma: the randomized controlled OUTERSPACE feasibility trial. Eur Respir J 2023; 62: Suppl. 67, OA3181.
Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention. 2023. Available from: http://ginasthma.org/
Louis R, Harrison TW, Chanez P, et al. Severe asthma standard-of-care background medication reduction with benralizumab: ANDHI in practice substudy. J Allergy Clin Immunol Pract 2023; 11: 1759–1770.
Jackson DJ, Heaney LG, Humbert M, et al. SHAMAL: reduction of maintenance inhaled corticosteroids in patients with severe eosinophilic asthma treated with benralizumab: a randomised phase 4 study. Eur Respir J 2023; 62: Suppl. 67, RCT798.
Jackson DJ, Pavord ID, Christian Virchow J, et al. The proportion of patients achieving low biomarker levels with tezepelumab treatment in the phase 3 NAVIGATOR study. Eur Respir J 2023; 62: Suppl. 67, OA1418.
Stolz D, Lugogo N, Lawson K, et al. Inhaled corticosteroid dose reduction with tezepelumab in patients with severe, uncontrolled asthma over 2 years. Eur Respir J 2023; 62: Suppl. 67, PA4721.
Smidt-Hansen T, Andersen HH, Pedersen LM, et al. Patients with severe asthma reducing ICS treatment during treatment with biologicals do not have more frequent exacerbations. Eur Respir J 2023; 62: Suppl. 67, PA636.
Domvri K, Tsiouprou I, Bakakos P, et al. Effect of mepolizumab on airways remodeling in patients with late-onset severe eosinophilic asthma and fixed obstruction (preliminary data of the MESILICO study). Eur Respir J 2023; 62: Suppl. 67, OA3152.
Shafiek H, Iglesias A, Mosteiro M, et al. Bronchial submucosal eosinophils predict clinical remission better than blood eosinophils and FENO in severe uncontrolled asthma treated with biological therapy. Eur Respir J 2023; 62: Suppl. 67, OA1413.
Tran T, Le TT, Scelo G, et al. Real world biologic treatment response in severe asthma: an analysis of the International Severe Asthma Registry (ISAR). Eur Respir J 2023; 62: Suppl. 67, PA1894.
Wechsler ME, Brusselle G, Virchow JC, et al. On-treatment clinical remission with tezepelumab in patients with severe, uncontrolled asthma in the phase 3 DESTINATION study. Eur Respir J 2023; 62: Suppl. 67, PA4722.
Brightling CE, Jackson D, Kotalik A, et al. Biomarkers and clinical outcomes after cessation of tezepelumab after 2 years of treatment (DESTINATION). Eur Respir J 2023; 62: Suppl. 67, OA1415.
Chaudhuri R, Liu MC, Bagnasco D, et al. Real-world outcomes with mepolizumab in patients with severe asthma and comorbid anxiety/depression: REALITI-A at 2 years. Eur Respir J 2023; 62: Suppl. 67, PA4757.
García Rivero JL, Bañas Conejero D. Multicentric real life experience of mepolizumab in bronchiectasis concomitant to severe asthma. Eur Respir J 2023; 62: Suppl. 67, PA1905.
ten Have L, Visser E, Sont JK, et al. Long-term weight changes after starting anti-interleukin-5/5Ra biologics in severe asthma. Eur Respir J 2023; 62: Suppl. 67, PA1896.
O’Carroll M, Huetsch J, Hamilton J, et al. A first-in-human study of ARO-RAGE, an RNAi therapy designed to silence pulmonary RAGE expression. Eur Respir J 2023; 62: Suppl. 67, OA2601.
Diamant Z, Lee Y, Yang W, et al. Effect of MMP-12 inhibitor, adermastat-(FP-025), on allergen-induced late response in asthmatic subjects. Eur Respir J 2023; 62: Suppl. 67, OA2494.
Wan Y, Gai J, Zhu M, et al. Phase I safety and tolerance study of the inhalable anti IL-4Rα single domain antibody, LQ036, demonstrates promising clinical profile to treat asthma. Eur Respir J 2023; 62: Suppl. 67, OA1412.
Deiteren A, Krupka E, Imberdis K, et al. Early improvement in asthma small airway dysfunction after one dose of SAR443765, a novel bispecific anti-thymic stromal lymphopoietin/anti-IL-13 nanobody molecule. Eur Respir J 2023; 62: Suppl. 67, OA4296.
Pisano AR, Fragni D, Allen A, et al. The inhaled PDE4 inhibitor tanimilast shows efficacy in both Th2 and non-Th2 murine models of asthma. Eur Respir J 2023; 62: Suppl. 67, OA4305.
El-Husseini Z, Khalenkow D, Lan A, et al. SIL-6Rα amplified IL-6 signaling in bronchial epithelial cells defines a subgroup of asthma patients low in sputum eosinophils. Eur Respir J 2023; 62: Suppl. 67, OA4300.
Oliver A, Madissoon E, Sungnak W, et al. Decoding the epithelial-T helper cell signalling axis in human asthmatic airways one cell at a time. Eur Respir J 2023; 62: Suppl. 67, OA774.
Peters U, Dixon A, Forno E. Obesity and asthma. J Allergy Clin Immunol 2018; 141: 1169–1179.
Tibbitt C, Björkander S, Maier P, et al. Innate lymphoid cells type 2 and CD8+ T cells are perturbed in overweight and obese individuals with asthma. Eur Respir J 2023; 62: Suppl. 67, OA2502.
Kabata H, Irie M, Baba R, et al. Zinc plays an essential role in type 2 cytokine production from ILC2s in asthma. Eur Respir J 2023; 62: Suppl. 67, OA2501.
Miguéns-Suárez P, Vázquez-Mera S, Martelo-Vidal L, et al. Mepolizumab alters the phenotype and activation status of peripheral blood eosinophils in patients with severe eosinophilic asthma. Eur Respir J 2023; 62: Suppl. 67, OA4301.
Bergantini L, d’Alessandro M, Pianigiani T, et al. Benralizumab affects NK cell maturation and proliferation in severe asthmatic patients. Clin Immunol 2023; 253: 109680.
Ghanizada M, Millgren SM, Said NM, et al. Effect of in vitro azithromycin treatment on epithelial antiviral immunity in eosinophilic and non-eosinophilic asthma phenotypes. Eur Respir J 2023; 62: Suppl. 67, OA4303.
Ricciardolo FLM, Sprio AE, Baroso A, et al. Characterization of T2-low and T2-high asthma phenotypes in real-life. Biomedicines 2021; 9: 1684.
Eastwood MC, Busby J, Kolmert J, et al. Urinary eicosanoids – novel biomarkers in T2-low severe asthma. Eur Respir J 2023; 62: Suppl. 67, OA1531.
Kolmert J, Gómez C, Balgoma D, et al. Urinary leukotriene E4 and prostaglandin D2 metabolites increase in adult and childhood severe asthma characterized by type 2 inflammation. A clinical observational study. Am J Respir Crit Care Med 2021; 203: 37–53.
Wheelock C, Chen Y, Checa A, et al. Identification of neutrophilic asthma via the ratio of sphingolipids to glucocorticoids. Eur Respir J 2023; 62: Suppl. 67, OA1532.
Liu L, Zhang X, Liu Y, et al. Chitinase-like protein YKL-40 correlates with inflammatory phenotypes, anti-asthma responsiveness and future exacerbations. Respir Res 2019; 20: 95.
Suzuki Y, Saito J, Rikimaru M, et al. Serum YKL-40 as a biomarker for predicting loss of lung function and neutrophilic airway inflammation in asthma, COPD and asthma–COPD overlap. Eur Respir J 2023; 62: Suppl. 67, OA3148.
De Volder J, Bontinck A, De Grove K, et al. Neutrophilic responses in a subacute and chronic mouse model of pollutant-aggravated allergic asthma. Eur Respir J 2023; 62: Suppl. 67, OA4211.
McGarvey L, Gibson PG. What is chronic cough? Terminology. J Allergy Clin Immunol Pract 2019; 7: 1711–1714.
Chung KF, Pavord ID. Prevalence, pathogenesis, and causes of chronic cough. Lancet 2008; 371: 1364–1374.
Adcock JJ. TRPV1 receptors in sensitisation of cough and pain reflexes. Pulm Pharmacol Ther 2009; 22: 65–70.
Song WJ, Morice AH. Cough hypersensitivity syndrome: a few more steps forward. Allergy Asthma Immunol Res 2017; 9: 394–402.
Chung KF, McGarvey L, Song W-J, et al. Cough hypersensitivity and chronic cough. Nat Rev Dis Primers 2022; 8: 45.
López-Cervantes JP, Lønnebotn M, Jogi NO, et al. The exposome approach in allergies and lung diseases: is it time to define a preconception exposome? Int J Environ Res Public Health 2021; 18: 12684.
Arinze JT, Verhamme KMC, Luik AI, et al. The interrelatedness of chronic cough and chronic pain. Eur Respir J 2021; 57: 2002651.
Song W-J, Chang Y-S, Faruqi S, et al. The global epidemiology of chronic cough in adults: a systematic review and meta-analysis. Eur Respir J 2015; 45: 1479–1481.
Satia I, Mayhew AJ, Sohel N, et al. Prevalence, incidence and characteristics of chronic cough among adults from the Canadian Longitudinal Study on Aging. ERJ Open Res 2021; 7: 00160-2021.
Yang C, Feng Z, Chen Z, et al. The risk factors for urinary incontinence in female adults with chronic cough. BMC Pulm Med 2022; 22: 276.
French CL, Irwin RS, Curley FJ, et al. Impact of chronic cough on quality of life. Arch Intern Med 1998; 158: 1657–1661.
Morice AH, Millqvist E, Bieksiene K, et al. ERS guidelines on the diagnosis and treatment of chronic cough in adults and children. Eur Respir J 2020; 55: 1901136.
Arismendi E, Puente-Maestu L, Dávila I, et al. Emotions associated with bouts of cough. A study in patients with refractory/unexplained chronic cough. Eur Respir J 2023; 62: Suppl. 67, PA3822.
Satia I, Wahab M, Kum E, et al. Chronic cough: investigations, management, current and future treatments. Can J Respir Crit Care Sleep Med 2021; 5: 404–416.
Dicpinigaitis PV, Morice AH, Smith JA, et al. Efficacy and safety of eliapixant in refractory chronic cough: the randomized, placebo-controlled phase 2b PAGANINI study. Lung 2023; 201: 255–266.
McGarvey LP, Birring SS, Morice AH, et al. Efficacy and safety of gefapixant, a P2X3 receptor antagonist, in refractory chronic cough and unexplained chronic cough (COUGH-1 and COUGH-2): results from two double-blind, randomised, parallel-group, placebo-controlled, phase 3 trials. Lancet 2022; 399: 909–923.
Birring SS, Passant C, Patel RB, et al. Chronic tonsillar enlargement and cough: preliminary evidence of a novel and treatable cause of chronic cough. Eur Respir J 2004; 23: 199–201.
McGarvey L, Smith J, Birring SS, et al. Response in patient-reported cough severity in SOOTHE, a phase 2b trial of camlipixant in refractory chronic cough. Am J Respir Crit Care Med 2023; 207: A2533.
King PT. The pathophysiology of bronchiectasis. Int J Chron Obstruct Pulmon Dis 2009; 4: 411–419.
Mocelin HT, Fischer GB, Piccini JD, et al. Surgical treatment of non-cystic fibrosis bronchiectasis in children and adolescents: a review. Paediatr Respir Rev 2023; 46: 57–62.
Shoemark A, Giam YH, Gilmour A, et al. Neutrophil metabolomics in bronchiectasis: data from the EMBARC BRIDGE study. Eur Respir J 2023; 62: Suppl. 67, OA1456.
Hull RC, Gilmour A, Mcintosh E, et al. Genetic diversity of Pseudomonas aeruginosa virulence factors in bronchiectasis. Eur Respir J 2023; 62: Suppl. 67, OA1463.
McShane PJ, Naureckas ET, Tino G, et al. Non–cystic fibrosis bronchiectasis. Am J Respir Crit Care Med 2013; 188: 647–656.
Wong C, Jayaram L, Karalus N, et al. Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial. Lancet 2012; 380: 660–667.
Altenburg J, de Graaff CS, Stienstra Y, et al. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis. JAMA 2013; 309: 1251–1259.
Serisier DJ, Martin ML, McGuckin MA, et al. Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis. JAMA 2013; 309: 1260–1267.
Aksamit TR, O’Donnell AE, Barker A, et al. Adult patients with bronchiectasis. Chest 2017; 151: 982–992.
Chalmers JD, Polverino E, Crichton ML, et al. Bronchiectasis in Europe: data on disease characteristics from the European Bronchiectasis registry (EMBARC). Lancet Respir Med 2023; 11: 637–649.
Chalmers JD, Aliberti S, Altenburg J, et al. Transforming clinical research and science in bronchiectasis: EMBARC3, a European Respiratory Society Clinical Research Collaboration. Eur Respir J 2023; 61: 2300769.
Chang AB, Grimwood K, Gibson PG, et al. PBB: definition, mechanisms, and treatment. Lancet Respir Med 2015; 3: 743–744.
Polverino E, Goeminne PC, McDonnell MJ, et al. European Respiratory Society guidelines for the management of adult bronchiectasis. Eur Respir J 2017; 50: 1700629.
Pollock J, Polverino E, Crichton ML, et al. Blood eosinophils, inhaled corticosteroids and exacerbations in bronchiectasis: data from the EMBARC registry. Eur Respir J 2023; 62: Suppl. 67, OA1457.
Chalmers JD, Boersma W, Lonergan M, et al. Long-term macrolide antibiotics for the treatment of bronchiectasis in adults: an individual participant data meta-analysis. Lancet Respir Med 2019; 7: 845–854.
Chalmers JD, Haworth CS, Metersky ML, et al. Phase 2 trial of the DPP-1 inhibitor brensocatib in bronchiectasis. N Engl J Med 2020; 383: 2127–2137.
